ACXP (Acurx Pharmaceuticals Inc.) stock: $1.06, $5.9M market cap, $10.7M cash, -$4.8M EV, $8.7M fully diluted market cap. Next expected readout: Sep-27. Lead program: Ibezapolstat (Clostridium Difficile Infection Recurrence), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
Our approach is to develop antibiotic candidates with a Gram-positive selective spectrum (“GPSS®”) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (“DNA”) polymerase IIIC (“pol IIIC”), inhibiting DNA replication and leading to Gram-positive bacterial cell death.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 2 · ActiveModality: small molecule (antibiotic)
Aliases ACX-362E, GLS362E
Target DNA polymerase IIIC (pol IIIC)
Indications
C. difficile infection (CDI)(Phase 2)
Recurrent C. difficile infection (rCDI)(Phase 2)
Catalysts
— Q4 2026
Status note Phase 2 CDI trial completed. Company plans a pivotal Phase 3 in rCDI under FDA's LPAD pathway following the rCDI pilot; open-label pilot trial startup began Q2 2026 with first patient expected Q4 2026. Originated via Feb 2018 asset purchase from GLSynthesis.
ACX-375C
Preclinical · ActiveModality: small molecule (antibiotic)
Status note Early-stage candidate for oral and/or parenteral treatment of Gram-positive infections including MRSA, VRE, penicillin-resistant Streptococcus pneumoniae, and B. anthracis (anthrax); proof of concept established in animal studies.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.